I'm LongbridgeAI, I can summarize articles.U.S. stocks fell with the Nasdaq dropping over 100 points, yet several biotech and tech shares rose. TriSalus surged 5.8% on FDA clearance for TriNav Advance. Lakefront Biotherapeutics gained 6.8% following an analyst upgrade to Outperform with a $45 price target. Other gainers included Securitize (+8.1%), Maze Therapeutics (+4.6%) after a Wedbush reiteration, Moderna (+4.4%) on ESMO Congress abstracts, Editas Medicine (+4%) on a Guggenheim upgrade, Xeris Biopharma (+3.4%), Palantir (+3.3%), and Pulse Biosciences (+3%) on BTIG initiation.
U.S. stocks were lower, with the Nasdaq Composite falling over 100 points on Wednesday.
Shares of TriSalus Life Sciences Inc (NASDAQ:TLSI) rose sharply after the company announced it received FDA 510(k) clearance for TriNav Advance.
TriSalus Life Sciences shares jumped 5.8% to $5.22 on Wednesday.
Here are some other big stocks recording gains in today’s session.
- Securitize Corp (NYSE:SECZ) shares jumped 8.1% to $14.04.
- Lakefront Biotherapeutics NV – ADR (NASDAQ:LKFT) gained 6.8% to $32.24. RBC Capital analyst Brian Abrahams upgraded Lakefront Biotherapeutics from Sector Perform to Outperform and raised the price target from $26 to $45.
- Bandwidth Inc (NASDAQ:BAND) gained 6.4% to $62.18.
- Maze Therapeutics Inc (NASDAQ:MAZE) surged 4.6% to $29.68. Wedbush analyst Laura Chico reiterated Maze Therapeutics with an Outperform rating and maintained a $48 price target.
- Moderna Inc (NASDAQ:MRNA) rose 4.4% to $190.59. The company recently announced three abstracts on its mRNA-based individualized neoantigen therapy intismeran autogene have been accepted for presentation at the ESMO Congress 2026.
- Editas Medicine Inc (NASDAQ:EDIT) rose 4% to $3.04. Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine from Neutral to Buy and announced a $5 price target.
- Xeris Biopharma Holdings Inc (NASDAQ:XERS) gained 3.4% to $9.03.
- Palantir Technologies Inc (NASDAQ:PLTR) gained 3.3% to $191.00.
- Pulse Biosciences Inc (NASDAQ:PLSE) gained 3% to $54.26. BTIG analyst Marie Thibault initiated coverage on Pulse Biosciences with a Buy rating and announced a PRICE TARGEt of $70.
Photo via Shutterstock